Biosig Technologies (NASDAQ:STEX) Announces Quarterly Earnings Results

Biosig Technologies (NASDAQ:STEX) issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, Zacks reports.

Biosig Technologies Stock Performance

NASDAQ:STEX opened at $1.41 on Wednesday. The company has a 50-day moving average price of $1.15. Biosig Technologies has a 12 month low of $0.70 and a 12 month high of $14.11. The firm has a market capitalization of $256.34 million, a price-to-earnings ratio of -0.15 and a beta of 1.58.

Insider Activity

In related news, CIO Mitchell Young Williams sold 263,863 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $0.79, for a total value of $208,451.77. Following the completion of the transaction, the executive owned 3,037,648 shares in the company, valued at $2,399,741.92. The trade was a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Morgan Lee Lekstrom acquired 147,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was bought at an average price of $1.04 per share, with a total value of $152,880.00. Following the transaction, the chairman directly owned 269,500 shares in the company, valued at $280,280. The trade was a 120.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders sold 320,736 shares of company stock worth $269,659. 52.73% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC lowered their price objective on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 21st. Wall Street Zen downgraded shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Finally, Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.